Media headlines about Trinity Biotech (NASDAQ:TRIB) have trended somewhat positive on Sunday, according to Accern. The research firm ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Trinity Biotech earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 46.4228788042279 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Separately, ValuEngine downgraded Trinity Biotech from a “sell” rating to a “strong sell” rating in a research note on Saturday, April 21st.
Shares of Trinity Biotech traded down $0.05, reaching $4.46, during trading on Friday, Marketbeat.com reports. The company had a trading volume of 23,547 shares, compared to its average volume of 44,056. The company has a debt-to-equity ratio of 1.43, a quick ratio of 3.55 and a current ratio of 5.23. Trinity Biotech has a one year low of $4.22 and a one year high of $6.54. The company has a market capitalization of $94.39 million, a price-to-earnings ratio of 28.19 and a beta of 1.16.
Trinity Biotech Company Profile
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease, sexually transmitted diseases, respiratory infections, epstein barr virus, and other viral pathogens; and products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a high risk of developing diabetes.
Read More: Marijuana Stocks Investing Considerations
Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.